Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).
Efficacy and safety of once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).